SciSparc Ltd. (NASDAQ:SPRC) Sees Large Decrease in Short Interest

SciSparc Ltd. (NASDAQ:SPRC) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 34,600 shares, a drop of 93.4% from the August 15th total of 526,900 shares. Based on an average daily trading volume, of 3,240,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.4% of the shares of the company are short sold.

SciSparc Price Performance

SPRC traded up $0.01 during trading on Friday, reaching $0.30. 648,004 shares of the company were exchanged, compared to its average volume of 1,706,512. SciSparc has a 52 week low of $0.28 and a 52 week high of $14.22. The firm has a 50 day moving average of $0.45 and a 200 day moving average of $1.18.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in SciSparc stock. Renaissance Technologies LLC bought a new position in SciSparc Ltd. (NASDAQ:SPRC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned about 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is owned by hedge funds and other institutional investors.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.